Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue

被引:23
|
作者
Elzembely, Mahmoud M. [1 ,3 ]
Dahlberg, Ann E. [1 ,2 ]
Pinto, Navin [2 ]
Leger, Kasey J. [2 ]
Chow, Eric J. [2 ]
Park, Julie R. [2 ]
Carpenter, Paul A. [1 ,2 ]
Baker, K. Scott [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Clin Research Div, 1100 Fairview Ave N,Mail Stop D5-280, Seattle, WA 98109 USA
[2] Univ Washington, Seattle Childrens Hosp Seattle, Dept Pediat, Seattle, WA 98195 USA
[3] Assiut Univ, South Egypt Canc Inst, Pediat Oncol Dept, Assiut, Egypt
关键词
high-dose chemotherapy; late effects; neuroblastoma; LONG-TERM OUTCOMES; CANCER SURVIVORS; TRANSPLANTATION; CHILDREN; OTOTOXICITY; CISPLATIN; GROWTH;
D O I
10.1002/pbc.27421
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Current treatment strategies have improved the outcome of high-risk neuroblastoma (HRNB) at the cost of increasing acute and late effects of treatment. Although high-dose chemotherapy with stem cell rescue (HDC-SCR) has replaced total body irradiation (TBI) based HRNB therapy, late effects of therapy remain a significant concern. Objectives Methods To describe late effects prevalence, severity, and risks after HDC-SCR. Retrospective chart review of relapse-free HRNB survivors >= 1 year after single HDC-SCR between 2000 and 2015 at Fred Hutchinson Cancer Research Center. Results Conclusion Sixty-one survivors (30 males) were eligible. Median age (years) at SCR was 3.5 years (range 0.7-27 years) and median posttransplant follow-up was 5.4 years (1.2-16.3 years) . Fifty-three (86.9%) survivors developed late effects that increased over time (P < 0.001) and varied in severity from grade 1 (35) to grade 5 (1). These were unrelated to gender or age. High-frequency hearing loss seen in 82% of survivors was the most common abnormality present and 43% of those required hearing aids. Seventeen (27.9%) survivors developed dental late effects and these were most common in children <2 years of age at transplant (P = 0.008). Other toxicities included endocrine (18%), orthopedic (14.8 %), renal (3.9%), melanotic nevi (8.2%), neuropsychological impairments (8.2%), subsequent malignancies (4.9%), pulmonary (4.9%), cardiac (4.9%), and focal nodular liver hyperplasia (3.3%). At 9 years posttransplant, the median height and weight Z-scores were significantly lower than Z-scores at the time of HDC-SCR (-0.01/-1.08, P < 0.001; -0.14/-0.78, P = 0.005). Avoidance of TBI does not mitigate the need to provide diligent, ongoing surveillance for late effects.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Late Effects in High Risk Neuroblastoma Survivors Treated with High Dose Chemotherapy and Stem Cell Rescue
    Mohammed, Mahmoud
    Carpenter, Paul
    Park, Julie
    Baker, Kevin
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 : S73 - S73
  • [2] High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma
    Yalcin, Bilgehan
    Kremer, Leontien C. M.
    Caron, Huib N.
    van Dalen, Elvira C.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):
  • [3] High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma
    Yalcin, Bilgehan
    Kremer, Leontien C. M.
    van Dalen, Elvira C.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (10):
  • [4] High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma
    Yalcin, Bilgehan
    Kremer, Leontien C. M.
    Caron, Huib N.
    van Dalen, Elvira C.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (05):
  • [5] Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue
    Haghiri, Sandrine
    Fayech, Chiraz
    Mansouri, Imene
    Dufour, Christelle
    Pasqualini, Claudia
    Bolle, Stephanie
    Rivollet, Sophie
    Dumas, Agnes
    Boumaraf, Amel
    Belhout, Amel
    Journy, Neige
    Souchard, Vincent
    Vu-Bezin, Giao
    Veres, Cristina
    Haddy, Nadia
    De Vathaire, Florent
    Valteau-Couanet, Dominique
    Fresneau, Brice
    [J]. BONE MARROW TRANSPLANTATION, 2021, 56 (08) : 1984 - 1997
  • [6] Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue
    Sandrine Haghiri
    Chiraz Fayech
    Imène Mansouri
    Christelle Dufour
    Claudia Pasqualini
    Stéphanie Bolle
    Sophie Rivollet
    Agnès Dumas
    Amel Boumaraf
    Amel Belhout
    Neige Journy
    Vincent Souchard
    Giao Vu-Bezin
    Cristina Veres
    Nadia Haddy
    Florent De Vathaire
    Dominique Valteau-Couanet
    Brice Fresneau
    [J]. Bone Marrow Transplantation, 2021, 56 : 1984 - 1997
  • [7] Gonadal Failure Is Common in Long-Term Survivors of Childhood High-Risk Neuroblastoma Treated With High-Dose Chemotherapy and Autologous Stem Cell Rescue
    Utriainen, Pauliina
    Suominen, Anu
    Makitie, Outi
    Jahnukainen, Kirsi
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [8] TREATMENT OUTCOME OF HIGH-DOSE CHEMOTHERAPY PLUS STEM CELL RESCUE IN HIGH-RISK NEUROBLASTOMA IN THAILAND
    Suwannaying, Kunanya
    Techavichit, Piti
    Patcharee, Patcharee
    Laoaroon, Napat
    Narkbunnam, Nattee
    Sanpakit, Kleebsabai
    Chiengthong, Kanhatai
    Chotsampancharoen, Thirachit
    Sathitsamitphong, Lalita
    Santong, Chalongpon
    Seksarn, Panya
    Hongeng, Suradej
    Wiangnon, Surapon
    [J]. PEDIATRIC BLOOD & CANCER, 2022, 69 : S599 - S599
  • [9] Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma
    Martin, Alissa
    Schneiderman, Jennifer
    Helenowski, Irene B.
    Morgan, Elaine
    Dilley, Kimberley
    Danner-Koptik, Karina
    Hatahet, Mohamad
    Shimada, Hiroyuki
    Cohn, Susan L.
    Kletzel, Morris
    Hijiya, Nobuko
    [J]. PEDIATRIC BLOOD & CANCER, 2014, 61 (08) : 1350 - 1356
  • [10] Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand
    Suwannaying, Kunanya
    Techavichit, Piti
    Komvilaisak, Patcharee
    Laoaroon, Napat
    Narkbunnam, Nattee
    Sanpakit, Kleebsabai
    Chiengthong, Kanhatai
    Chotsampancharoen, Thirachit
    Sathitsamitphong, Lalita
    Santong, Chalongpon
    Seksarn, Panya
    Hongeng, Suradej
    Wiangnon, Surapon
    [J]. CLINICAL AND EXPERIMENTAL PEDIATRICS, 2022, 65 (09) : 453 - 458